（2）团体订购 浙江奥康鞋业股份有限公司2025 年半年度报告 公司代码：603001 公司简称：奥康国际 浙江奥康鞋业股份有限公司 浙江奥康鞋业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王振滔、主管会计工作负责人王晨及会计机构负责人（会计主管人员）陈钦河 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述因存在不确定，不构成公司对投资者的实质 承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 无 十一、 ...

Group 1 - The company announced on July 11 that its controlling shareholder and actual controller, Wang Zhentao, is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [1] - The specific plan for the change is still under consideration, and no agreements have been signed yet, with discussions ongoing regarding the transaction [1][4] - To ensure fair information disclosure and avoid abnormal stock price fluctuations, the company applied for a trading suspension starting July 14, expected to last no more than two trading days [4] Group 2 - On July 11, the company's stock opened lower but closed up significantly by 16.2%, with a closing price of 72.01 yuan per share and a total trading volume of 1.08 billion yuan, indicating a notable increase in trading activity compared to the average turnover rate of 2.94% over the previous 30 trading days [4] - The company primarily engages in the research, production, and sales of human vaccines, having obtained registration certificates for vaccines such as the freeze-dried human rabies vaccine and the ACYW135 group meningococcal polysaccharide vaccine [4] - Wang Zhentao, known as the "Shoe King" of Wenzhou, has faced significant pressure on the company's performance, with a reported net profit decline of over 80% year-on-year in the first quarter [5] Group 3 - In the first quarter, the company reported revenue of approximately 138 million yuan, a decrease of 55.7% year-on-year, and a net profit attributable to shareholders of approximately 20.71 million yuan, down 86.15% year-on-year [5] - The company's revenue has declined for three consecutive years, with projected revenues of approximately 1.447 billion yuan, 1.577 billion yuan, and 1.432 billion yuan for 2022, 2023, and 2024, respectively [5] - The overall vaccine industry is facing pressure, with many companies experiencing revenue and profit declines, necessitating adjustments in business strategies to cope with market competition and innovation challenges [5]